Significantly reduces seizures! Advances in the application of iPSC in neurological disorders

September 26, 2022 / eMedClub News /-Recently, Neurona Therapeutics has released the latest data
from a Phase 1/2 clinical trial of its neuronal cell therapy drug NRTX-1001 derived from human pluripotent stem cells (iPSC) for the treatment of medial temporal lobe epilepsy (MTLE).

MTLE is the most common type of focal epilepsy in adults, affecting primarily the internal structure of the temporal lobe, and seizures usually begin with a structure
called the hippocampus.

NRTX-1001 is a neuronal cell therapy drug derived from human pluripotent stem cells using Neurona's proprietary manufacturing process
.

iPSC and the treatment of neurological disorders

Neurodegenerative diseases are a class of diseases that lead to dysfunction due to the gradual loss or even death of neuronal structure or function, including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease and spinal muscular atrophy; At present, the cause of such diseases is not clear and cannot be cured
.

ALF201, the main candidate therapy for stroke ➤ Lennuo Medicine, is an injection of heterointernal intracorpodial progenitor cells (EPCs) based on iPSC directional induction of differentiation, which is intended for the treatment of acute ischemic stroke of
the aortrosclerotic type.

The therapy was approved clinically in April this year, making it the world's first approved clinical candidate for acute ischemic stroke
.
➤ Hodder has developed an iPSC-derived candidate cell therapy hNPC-01 with indications for stroke, head injury, and cerebral palsy, and the company is currently planning to file a Sino-US IND application
for the treatment of hemiplegia sequelae.

In addition, the company has developed alternative therapies for other neurological disorders, such as frostbite and spinal cord injury (hNPC-02), which are currently in the preclinical research phase
.
In December 2021, a team at Keio University Hospital completed the first clinical trial
of transplanting human iPS cell-derived nerve stem/progenitor cells (hiPSC-NS/PCs) into the spinal cord of patients with spinal cord injury.

The procedure is the world's first human-induced iPSC-NS/PCs spinal cord injury transplant
.
Recommended reading: Japan completed the first case of iPSC transplantation for the treatment of spinal cord injury clinical trialmedical Mai Meng broke the news
, there is also a study using iPSC technology to build a frostbite disease model, for the drug screening of amyotrophic lateral sclerosis (ALS), while establishing a "multiple disease model" to classify ALS diseases, in vitro to verify whether the efficacy of drugs on different types of patients is affected
by patient heterogeneity.

Resources:

1.